Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYLOREL vs NORMODYNE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits sympathetic vasoconstriction, reducing peripheral vascular resistance and blood pressure.
Competitive antagonist at beta-1 adrenergic receptors with additional alpha-1 adrenergic receptor blocking activity, resulting in vasodilation and decreased heart rate, contractility, and cardiac output.
Hypertension,Benign prostatic hyperplasia
Hypertension,Pheochromocytoma (preoperative management),Hypertensive crisis (off-label)
10 mg orally twice daily, titrated to 20-40 mg twice daily based on blood pressure response.
Oral: Initial 100 mg twice daily, increase by 100 mg/day every 2 weeks; maintenance 200-400 mg twice daily. Max 1200 mg/day. IV: 20 mg (1 m L) over 2 minutes, repeat if needed at 10 min intervals up to total 300 mg.
Approximately 12-15 hours; clinically, steady-state achieved in 2-3 days.
8-12 hours; extended in hepatic impairment (up to 20 hours) and renal impairment (up to 15 hours)
Extensively metabolized in the liver via O-demethylation and conjugation; CYP450 enzymes involved (CYP2D6, CYP3A4).
Primarily hepatic via glucuronidation and sulfation; first-pass effect; CYP2D6 minor role.
Primarily renal (50-60% unchanged) and biliary/fecal (40-50%).
Renal: 55-65% as unchanged drug and metabolites; Fecal: ~20% via bile; Hepatic metabolism: ~25%
90-95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Labetalol: ~50% bound to albumin
0.5-0.7 L/kg; indicates distribution into total body water.
11 L/kg (extensive tissue distribution, including placenta and breast milk)
85-90% after oral administration.
Oral: 25-40% due to extensive first-pass metabolism; IV: 100%
No adjustment needed for mild to moderate renal impairment (GFR 30-89 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor blood pressure closely.
GFR > 50 m L/min: No adjustment. GFR 10-50 m L/min: Reduce dose by 50% or prolong interval. GFR < 10 m L/min: Use with caution; consider 50% dose reduction.
For Child-Pugh Class A: no adjustment. For Class B: reduce starting dose to 5 mg twice daily, titrate cautiously. For Class C: avoid use due to lack of safety data.
Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; reduce dose by 50%. Child-Pugh C: Contraindicated.
Not recommended in pediatric patients due to lack of safety and efficacy data.
Oral: 0.25-1 mg/kg/dose twice daily; increase gradually. Max 2 mg/kg/day (up to 120 mg/day). IV: 0.1-0.2 mg/kg over 2 minutes; may repeat every 10 min up to 1 mg/kg total.
Start at 5 mg twice daily, titrate slowly; monitor for orthostatic hypotension and electrolyte imbalances due to age-related changes in renal function and sympathetic response.
Start at lowest dose (100 mg twice daily oral); titrate slowly. Monitor orthostatic hypotension and bradycardia. IV use with caution; reduce initial dose to 10 mg.
None
Exacerbation of angina pectoris and myocardial infarction may occur following abrupt discontinuation of beta-blocker therapy.
Syncope and orthostatic hypotension,Priapism,Intraoperative floppy iris syndrome,Use in patients with impaired hepatic function
Congestive heart failure,Bronchospasm in patients with asthma/COPD,Hepatic injury,Hypotension/syncope,Masking of hypoglycemia in diabetics,Thyrotoxicosis symptoms masked,Abrupt discontinuation leading to rebound hypertension/angina
Hypersensitivity to guanadrel or similar drugs,Concomitant use with MAO inhibitors
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Overt cardiac failure,Hypersensitivity to labetalol or any component
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as guanethidine may potentiate pressor effects. Also avoid excessive alcohol consumption due to additive hypotensive effects. Take with food to reduce GI upset.
Take with food to enhance absorption. Avoid excessive alcohol intake as it may increase hypotensive effects. Grapefruit juice may increase drug levels; limit consumption.
Pregnancy Category C. First trimester: No adequate studies, but potential for fetal harm based on animal data (skeletal abnormalities, reduced fetal weight at high doses). Second and third trimesters: May cause fetal bradycardia, hypotension, and reduced placental perfusion; avoid use due to risk of oligohydramnios and fetal renal impairment.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause fetal hypotension, bradycardia, and growth restriction; risk of neonatal hypotension, bradycardia, and hypoglycemia if used near term. Avoid in preeclampsia due to risk of fetal distress.
Excreted in human milk in small amounts; M/P ratio unknown. Use caution in nursing mothers, especially in preterm neonates due to potential for hypotension and bradycardia. Monitor infant for sedation, poor feeding, and hypotonia.
Excreted in breast milk in low concentrations (M/P ratio ~1.3). Considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Due to increased plasma volume and renal clearance in pregnancy, guanfacine levels may decrease; however, dose adjustment not routinely recommended due to limited data. Use lowest effective dose. Avoid use in preeclampsia or volume-depleted states. No specific guidelines for dose increase.
Increased hepatic clearance and volume of distribution in pregnancy may require higher doses; individualize based on maternal response.
HYLOREL (guanethidine) is a potent adrenergic neuron blocker used primarily for moderate to severe hypertension. Its use is limited due to orthostatic hypotension and dose-related side effects. Initiate at low doses (10 mg/day) and titrate slowly. Avoid in patients with pheochromocytoma or MAOI use within 14 days. Monitor for profound orthostasis, especially upon waking and after exercise. May cause diarrhea due to increased GI motility. Combine with a diuretic to reduce dose requirements and enhance efficacy.
Normodyne (labetalol) is a non-selective beta-blocker with alpha-1 blocking activity. It causes less reflex tachycardia than pure vasodilators. Bioavailability increases with food. Dosing should be titrated. Abrupt withdrawal may exacerbate angina or hypertension. Use cautiously in asthma, COPD, and heart failure.
Take exactly as prescribed; do not stop abruptly as this may cause rapid blood pressure increase.,Arise slowly from sitting or lying to prevent dizziness and fainting. Avoid sudden position changes.,Avoid alcohol and over-the-counter cold or allergy medications unless approved by your doctor.,May cause drowsiness; use caution when driving or operating machinery.,Report persistent dizziness, fainting, or severe diarrhea to your healthcare provider.,Maintain adequate fluid intake, but avoid excessive salt unless directed.,Inform all healthcare providers of your use of this medication before any surgery.
Take exactly as prescribed; do not stop suddenly as this may cause a rapid rise in blood pressure.,May cause dizziness or lightheadedness; avoid driving or operating machinery until you know how you react.,Do not take over-the-counter cold or allergy medications without consulting your doctor.,Inform your doctor if you experience slow heartbeat, shortness of breath, or swelling of extremities.,If you have diabetes, monitor blood sugar closely as labetalol may mask signs of hypoglycemia.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYLOREL vs NORMODYNE, answered by our medical review team.
HYLOREL is a Antihypertensive Agent that works by Selective alpha-1 adrenergic receptor antagonist; inhibits sympathetic vasoconstriction, reducing peripheral vascular resistance and blood pressure.. NORMODYNE is a Antihypertensive Agent that works by Competitive antagonist at beta-1 adrenergic receptors with additional alpha-1 adrenergic receptor blocking activity, resulting in vasodilation and decreased heart rate, contractility, and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYLOREL and NORMODYNE depend on the specific clinical indication. These are both Antihypertensive Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYLOREL is: 10 mg orally twice daily, titrated to 20-40 mg twice daily based on blood pressure response.. The standard adult dose of NORMODYNE is: Oral: Initial 100 mg twice daily, increase by 100 mg/day every 2 weeks; maintenance 200-400 mg twice daily. Max 1200 mg/day. IV: 20 mg (1 m L) over 2 minutes, repeat if needed at 10 min intervals up to total 300 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYLOREL and NORMODYNE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYLOREL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies, but potential for fetal harm based on animal data (skeletal abnormalities, reduced fetal weight at high doses). Second a. NORMODYNE is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause fetal hypotension, bradycardia, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.